Relmada Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference

NEW YORK, June 9, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that Sergio Traversa, Chief Executive Officer of Relmada, will participate in a fireside chat at the Goldman Sachs 41st Annual Global Healthcare Conference, being held June 9-11, 2020.


Fireside Chat Details:


Thursday, June 11, 2020


3:00 PM EDT


A live webcast of the fireside chat will be available by visiting the "Investors" section of the company's website: A replay of the webcast will be available for 90 days following the conclusion of the live presentation broadcast.


About Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel medicines to address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. Relmada's lead program, REL-1017 (dextromethadone) is an N-methyl-D-aspartate (NMDA) receptor antagonist in development for the treatment of depression.  NMDA receptor antagonists may have utility in the treatment of a range of psychiatric and neurological disorders associated with a variety of cognitive, neurological and behavioral symptoms.

Investor Contact:

Tim McCarthy  
LifeSci Advisors  

For Media Inquiries:
FischTank PR 

Cision View original content to download multimedia:

SOURCE Relmada Therapeutics, Inc.